Navigation Links
Regulatory Leader in OASIS Documentation Introduces OASIS-C Products
Date:10/12/2009

DES MOINES, Iowa, Oct. 12 /PRNewswire/ -- Briggs, a leading provider of solutions to improve clinical outcomes and reduce operating costs in the home care market, today announced new OASIS-C products to meet extensive regulatory changes mandated by the Centers for Medicare & Medicaid Services (CMS).

The new OASIS-C products include Briggs' proprietary documentation for all OASIS assessment forms as well as a new online training course to support the regulatory changes.

The OASIS-C assessment enables home health care providers to capture more data while reducing the chance for errors and omissions in patient documentation. In addition to affecting the patients' program of care, errors and omissions can impact an agency's regulatory compliance, delay or minimize reimbursements and increase operating costs.

"Briggs' OASIS-C assessments include proprietary information to address three key areas: addressing problems before they become serious, treating existing conditions as efficiently as possible and intervention prior to re-hospitalization," says Sharon Hamilton, RN, BAB, CNLCP, CFDS, Briggs' Clinical Consultant-Home Care. "Unlike other assessments, Briggs provides the safeguards agencies need to stay compliant and maximize reimbursements."

Briggs backs up its new OASIS-C documentation with an online training course, accessible to home care clinicians through their computer. The 7-hour, 11 section course covers all the CMS changes, uses interactive modules to fully engage participants and offers pre- and post-testing features to help gauge improving proficiency.

In developing the OASIS-C products, Briggs has built on its core competencies as the regulatory leader in OASIS documentation. According to an independent study conducted by OCS, Inc., home care agencies using Briggs' OASIS forms report better outcomes for all CMS measurements, lower occurrence rates, reduced resource utilization and reduced costs per visit.

For more information regarding Briggs OASIS-C products, visit www.BriggsCorp.com/OASIS.

About Briggs

Briggs is a leading supplier to more than 50,000 healthcare customers in the senior care, home care, acute care, physician and retail markets. Briggs produces and distributes more than 10,000 products including proprietary medical forms and documentation systems, durable and disposable medical supplies, charting materials and professional resources. Backed by clinical experience and regulatory knowledge, the company develops and markets products that are designed to improve clinical outcomes and reduce operating costs. The company has extensive international production capabilities and serves customers in five continents. For more information about Briggs, visit www.BriggsCorp.com

Media Contact: Brooke Kelley, Public Relations Specialist, 1.800.247.2343, kelley.brooke@briggscorp.com

SOURCE Briggs


'/>"/>
SOURCE Briggs
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. EpiCept Reports Regulatory Progress on Ceplene(TM)
2. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
3. Anesiva Defines Regulatory Pathway for Adlea with FDA
4. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
5. EpiCept Provides Update on Clinical and Regulatory Progress with Ceplene(TM) and EpiCept(TM) NP-1 Cream
6. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
7. Gen-Probe Submits U.S. Regulatory Application for Additional Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay
8. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
9. PulmoBioTech Announces Details of Its Regulatory Approval Experiments
10. Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis
11. XTENT Announces European Regulatory Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... -- OrthoAccel ® Technologies, Inc. announces that the ... Effect of Vibration on Molar Distalization," a study that ... Jay Bowman , this prospective, peer-reviewed clinical study concluded ... ® speeds up molar distalization rates in the ... days to move the upper molars into a normal, ...
(Date:1/17/2017)... 2017   Tocagen Inc ., a clinical-stage, cancer-selective gene therapy ... president, research and pharmaceutical development at Tocagen, will present at ... Jan. 17-20 in Miami . ... ... for replicating viruses - what to do when and why Date ...
(Date:1/17/2017)... Jan. 17, 2017  EMD Serono, the biopharmaceutical business ... in the U.S. and Canada , ... joined the company as Senior Vice President and Head ... Smith will oversee the Fertility and Endocrinology businesses in ... launched its first product last year with Gidget™, a ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate its ... Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center in ... the gold standard for high-definition, in-ear earphones. This classic earphone has been updated ...
(Date:1/17/2017)... ... January 17, 2017 , ... Mirror Mirror Beauty Boutique, Houston’s premiere CoolSculpting ... Level in Zeltiq’s Crystal Rewards Program. Practice founder, Paul Vitenas, MD FACS, is delighted ... providers. , Produced by Zeltiq, CoolSculpting is approved by the Food and Drug ...
(Date:1/17/2017)... ... January 17, 2017 , ... Surgeons from New York’s ... care practitioners on the latest breakthroughs in the prevention, diagnosis and treatment of ... according to eye surgeon, Jeffrey Martin, MD, FACS, Chief Executive Officer of SightMD ...
(Date:1/17/2017)... ... ... Neil H. Greco Insurance Agency, a northern New Jersey firm that provides ... a charity drive to raise awareness of heart disease and promote habits that improve ... is responsible for 1 in every 4 deaths at the national level each year. ...
(Date:1/17/2017)... ... January 17, 2017 , ... Livionex, Inc., a Silicon Valley healthcare ... blind clinical study for its dental gel that shows significant reduction in plaque levels ... containing triclosan. The study was conducted at the Beckman Laser Institute at UC Irvine ...
Breaking Medicine News(10 mins):